AbbVie stock has returned 150.7% over the past five years, yet its current checks present a split picture, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to significant upside while market based multiples lean the other way.

• A 150.7% return over five years signals that AbbVie has already rewarded long term holders, which can make fresh valuation calls more sensitive to what happens next.
• On the upside, expectations around continued contributions from key immunology drugs and new approvals can support future cash flows. However, heightened competition from emerging therapies in core areas is a clear risk to that outlook.
• AbbVie screens as undervalued on only 2 of 6 checks. This means that, overall, the stock does not screen as a straightforward bargain on the broader valuation tests despite the DCF based upside.

The issue now is whether AbbVie’s current price better reflects the optimistic intrinsic value estimate or the more cautious signals coming from the wider valuation checks.

Is AbbVie Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what AbbVie is worth today based on the cash it is expected to generate in the future. For AbbVie, the latest twelve month free cash flow sits at about $20.1b, and the 2 Stage Free Cash Flow to Equity model assumes these cash flows continue growing from this base rather than shrinking.

On that basis, the DCF points to an intrinsic value of about $455 per share, which is roughly 46.4% above the current share price of around $250. The recent European Commission approval for Tepkinly in follicular lymphoma adds another source of potential future cash flows, which helps explain why the cash flow based valuation presents AbbVie as more attractive than some of the market multiples suggest.

Put together, the cash flow projections and current price suggest AbbVie stock may be undervalued on this DCF view.

Our Discounted Cash Flow (DCF) analysis suggests AbbVie is undervalued by 46.4%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Is AbbVie Getting Expensive on Earnings?

The P/E ratio fits AbbVie well because earnings remain a key yardstick for mature, cash generative pharma companies. Right now, AbbVie trades on a P/E of about 120.0x, which is much higher than both the biotech industry average of roughly 17.4x and a peer group average of about 21.4x.

The fair P/E ratio that reflects AbbVie’s size, margins and risk profile is estimated at around 42.3x, still well below where the stock currently sits. That leaves a wide gap between what investors are paying for each dollar of AbbVie’s earnings and what this model suggests would be more typical for a company with its characteristics.

On this earnings multiple, AbbVie stock currently appears overvalued relative to its fair P/E benchmark.

The AbbVie Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for AbbVie pick up where this valuation puzzle leaves off by spelling out the specific paths for AbbVie’s growth, margins and earnings that would need to play out for the stock to be worth materially more or less than today’s price, and they sit on Simply Wall St’s Community page. Each narrative links its number to a clear view on how AbbVie’s growth, profitability and risks might evolve, giving you a reference point to revisit as new information comes through.

Be one of the early voices in the Simply Wall St community to put a clear, number driven case on AbbVie, including your view on how developments like Tepkinly’s new European approval or fresh psoriasis competition might influence where its growth, margins and execution go from here.

Share your narrative, pin a valuation and thesis to those drivers, and then track how it holds up as AbbVie’s results, pipeline updates and regulatory decisions play out.

Do you think there's more to the story for AbbVie? Head over to our Community to see what others are saying!

The Bottom Line

AbbVie sits between an intrinsic value view that screens it as undervalued and market multiples that flag the stock as overvalued, so the valuation case is not straightforward. The Discounted Cash Flow (DCF) model leans on AbbVie’s ability to keep turning its pipeline and existing drugs into sizeable, durable cash flows. The richer P/E multiple, by contrast, reflects what investors are currently willing to pay for those earnings versus peers. The key question from here is whether AbbVie’s earnings power and cash generation can keep justifying that premium without being eroded by competition in its core franchises.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.